News and Trends 2 Nov 2017
AstraZeneca and Moderna want to beat Novartis at Treating Heart Failure
AstraZeneca will work with Moderna Therapeutics to bring together to the market an mRNA version of Novartis’ failed heart failure drug Serelaxin. AstraZeneca has signed a deal with US biotech Moderna Therapeutics to co-develop and co-commercialize an mRNA drug encoding for the protein hormone relaxin. The therapy has the same target as Novartis’ Serelaxin (RLX030), a drug that was dropped in March […]